Cowen analyst Tyler Van Buren upgraded Regeneron Pharmaceuticals to Outperform from Market Perform with a price target of $875, up from $775.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
- Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent
- Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis
- Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations